Acessa Health, Inc.

6 articles about Acessa Health, Inc.

• New Clinical Results from the Acessa System to be Presented at AAGL Global Congress on Minimally Invasive Gynecology

  11/11/2019

  The Acessa Procedure is specifically designed to treat women suffering from uterine fibroids and is clinically proven with long-term data as a safe alternative to hysterectomy and myomectomy.

• Acessa Health Inc. Featured in Podium Presentation at AAGL 2018

  11/13/2018

  Acessa Health Inc., developer of the Acessa System®, announced today that its laparoscopic radiofrequency ablation technology was featured at the 47th American Association of Gynecologic Laparoscopists (AAGL) Global Congress on Minimally Invasive Gynecologic Surgery (MIGS).

• Acessa Health Announces First Cases of Uterine Fibroid Treatment with Newly FDA-Cleared Acessa ProVu System

  11/1/2018

  Third-generation technology enhances the Acessa Procedure’s safe and effective treatment alternative to hysterectomy

• Acessa Health Receives FDA Clearance for the Acessa ProVu System® - The Next Generation Advancement in Uterine Fibroid Treatment

  10/2/2018

  Acessa Health Inc., developer of the Acessa System®, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and U.S. commercial availability of the Acessa System’s most advanced and proprietary technology, the Acessa ProVu System.

• Congressional Black Caucus 2018 - Acessa Health Partners with The White Dress Project to Present on Healthcare Disparities and Uterine Fibroids

  9/13/2018

  Exclusive Coverage of Healthcare Policy, Patient Access, Outcomes and Disparities in Treatment, Which Impact African American Women.

• Acessa Health Technology Featured In Ten-Year Review Of Symptomatic Fibroid Management

  9/8/2017